<DOC>
	<DOC>NCT02708056</DOC>
	<brief_summary>The objective of this study is to evaluate the efficacy and safety of sugammadex in reversing profound neuromuscular block induced by rocuronium in infant patients</brief_summary>
	<brief_title>Sugammadex Given for the Reversal of Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants</brief_title>
	<detailed_description />
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Rocuronium</mesh_term>
	<mesh_term>Sevoflurane</mesh_term>
	<criteria>Patients between the ages of 112 month, ASA physical status 13 who underwent elective brain cancer surgery during general anesthesia were included in the study younger than 1month or older than 12 months. hepatic or renal failure A history of allergy to study medication</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Sugammadex</keyword>
	<keyword>Rocuronium</keyword>
	<keyword>Infant patients</keyword>
</DOC>